trending Market Intelligence /marketintelligence/en/news-insights/trending/2jt0VvjN_TLNbnR8qwW_CA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Recordati buys global rights to 2 Novartis drugs for rare disease in $390M deal

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Recordati buys global rights to 2 Novartis drugs for rare disease in $390M deal

Italy's Recordati Industria Chimica e Farmaceutica SpA has completely acquired worldwide rights to two of Novartis AG's treatments for a rare disease in a $390 million deal.

The acquisition covers Switzerland-based Novartis' Cushing's disease drug Signifor and its extended-release version, Signifor LAR. It also includes global rights for the company's experimental drug osilodrostat, or LCI699, aimed to treat Cushing's syndrome, for which Novartis has filed marketing applications in the U.S. and Europe.

Cushing's is a severe endocrine disease caused by an enlargement in the pituitary gland that results in overproduction of the body's main stress hormone, cortisol.

As part of the deal, the Swiss pharmaceutical giant is also eligible for subsequent milestone payments tied to approval and market access of osilodrostat and royalties from the sales.

Recordati previously said it would fund the transaction from existing liquidity and new debt facilities.